Semaphorin-4D/SEMA4D Protein, Human (HEK293, His-Avi)

Semaphorin-4D/SEMA4D protein, a receptor for PLXNB1 and PLXNB2, regulates cell-cell signaling. It promotes inhibitory synapse development via PLXNB1, modulates neurite arborization through RHOA activation, and enhances viability of B-cells. SEMA4D induces endothelial cell migration via PTK2B/PYK2, SRC, and PI3K-AKT pathway. It forms homodimers and interacts with PLXNB2 and PLXNB1. Semaphorin-4D/SEMA4D Protein, Human (HEK293, His-Avi) is the recombinant human-derived Semaphorin-4D/SEMA4D protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Semaphorin-4D/SEMA4D Protein, a cell surface receptor for PLXNB1 and PLXNB2, plays a crucial role in cell-cell signaling. It is involved in regulating GABAergic synapse development and promotes the development of inhibitory synapses in a PLXNB1-dependent manner. By activating PLXNB1 and interacting with it, SEMA4D modulates the complexity and arborization of developing neurites in hippocampal neurons, mediating the activation of RHOA. Additionally, SEMA4D promotes the migration of cerebellar granule cells and induces B-cells to aggregate, enhancing their viability in vitro. In the immune system, SEMA4D plays a role in inducing endothelial cell migration through the activation of PTK2B/PYK2, SRC, and the phosphatidylinositol 3-kinase-AKT pathway. It forms homodimers and interacts with PLXNB2, as well as interacts with PLXNB1.

Human

HEK293

C-Avi;C-8*His

Q92854-1 (M22-R734)

10507  [NCBI]

Extracellular Domain

MAFAPIPRITWEHREVHLVQFHEPDIYNYSALLLSEDKDTLYIGAREAVFAVNALNISEKQHEVYWKVSEDKKAKCAEKGKSKQTECLNYIRVLQPLSATSLYVCGTNAFQPACDHLNLTSFKFLGKNEDGKGRCPFDPAHSYTSVMVDGELYSGTSYNFLGSEPIISRNSSHSPLRTEYAIPWLNEPSFVFADVIRKSPDSPDGEDDRVYFFFTEVSVEYEFVFRVLIPRIARVCKGDQGGLRTLQKKWTSFLKARLICSRPDSGLVFNVLRDVFVLRSPGLKVPVFYALFTPQLNNVGLSAVCAYNLSTAEEVFSHGKYMQSTTVEQSHTKWVRYNGPVPKPRPGACIDSEARAANYTSSLNLPDKTLQFVKDHPLMDDSVTPIDNRPRLIKKDVNYTQIVVDRTQALDGTVYDVMFVSTDRGALHKAISLEHAVHIIEETQLFQDFEPVQTLLLSSKKGNRFVYAGSNSGVVQAPLAFCGKHGTCEDCVLARDPYCAWSPPTATCVALHQTESPSRGLIQEMSGDASVCPDKSKGSYRQHFFKHGGTAELKCSQKSNLARVFWKFQNGVLKAESPKYGLMGRKNLLIFNLSEGDSGVYQCLSEERVKNKTVFQVVAKHVLEVKVVPKPVVAPTLSVVQTEGSRIATKVLVASTQGSSPPTPAVQATSSGAITLPPKPAPTGTSCEPKIVINTVPQLHSEKTMYLKSSDNR

Approximately 115-140 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

≥ 95%, as determined by Bis-Tris PAGE.

<1 EU/μg, determined by LAL method.